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Atypical hemolytic uremic syndrome (aHUS) is a severe disease characterized by
microvascular endothelial cell (EC) lesions leading to thrombi formation, mechanical
hemolysis and organ failure, predominantly renal. Complement system overactivation
is a hallmark of aHUS. To investigate this selective susceptibility of the microvascular
renal endothelium to complement attack and thrombotic microangiopathic lesions, we
compared complement and cyto-protectionmarkers on EC, from different vascular beds,
in in vitro and in vivo models as well as in patients. No difference was observed for
complement deposits or expression of complement and coagulation regulators between
macrovascular and microvascular EC, either at resting state or after inflammatory
challenge. After prolonged exposure to hemolysis-derived heme, higher C3 deposits
were found on glomerular EC, in vitro and in vivo, compared with other EC in culture and
in mice organs (liver, skin, brain, lungs and heart). This could be explained by a reduced
complement regulation capacity due to weaker binding of Factor H and inefficient
upregulation of thrombomodulin (TM). Microvascular EC also failed to upregulate the
cytoprotective heme-degrading enzyme heme-oxygenase 1 (HO-1), normally induced by
hemolysis products. Only HUVEC (Human Umbilical Vein EC) developed adaptation to
heme, which was lost after inhibition of HO-1 activity. Interestingly, the expression of KLF2
and KLF4—known transcription factors of TM, also described as possible transcription
modulators of HO-1- was weaker in micro than macrovascular EC under hemolytic
conditions. Our results show that the microvascular EC, and especially glomerular EC,
fail to adapt to the stress imposed by hemolysis and acquire a pro-coagulant and
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complement-activating phenotype. Together, these findings indicate that the vulnerability
of glomerular EC to hemolysis is a key factor in aHUS, amplifying complement
overactivation and thrombotic microangiopathic lesions.
Keywords: atypical hemolytic uremic syndrome, complement system, endothelial cells, heme, heme oxygenase-1,
thrombomodulin
INTRODUCTION
The atypical hemolytic uremic syndrome (aHUS) is a rare,
kidney-predominant, thrombotic microangiopathy (TMA)
associated with the formation of fibrin-platelet clots in
microvessels which trigger mechanical hemolysis (1). A
dysregulated complement alternative pathway (AP) plays a
key role in aHUS, as suggested by genetic abnormalities in AP
proteins found in up to 60% of patients (2, 3) and the efficacy of
anti-C5 therapy (4). Although the complement overactivation is
systemic, a particular renal tropism of the TMA lesions exists,
and injury of others organs is unusual in aHUS (5–10% of
patients) (2, 5).
This susceptibility of renal endothelial cells (EC) to
complement overactivation remains poorly understood. Despite
the morphologic and functional differences between glomerular
EC and other microvascular EC, no major differences were
observed in the basal expression of complement regulators or
complement component C3 deposits in resting state (6–10). The
high expression of complement proteins in kidneys could explain
the greater susceptibility of glomerular EC to complement attack.
The EC-derived C3 and Factor B are, however, present at lower
concentrations in kidney compared to the liver-derived C3 and
FB in blood, to which endothelium is exposed in vivo. Additional
factors are necessary to fully explain the vulnerability of the
glomerular endothelium to complement-mediated injury and
TMA in aHUS.
Cell-free hemoglobin and heme, released during hemolysis,
are potent promoters of pro-inflammatory and pro-oxidant
effects (11–13) and can induce EC phenotypical changes,
affording them complement activating properties (8, 14,
15). Under hemolytic conditions EC also up-regulate the
cytoprotective heme-degrading enzyme heme oxygenase 1
(HO-1) (15), and this overexpression was associated with
increased resistance to complement activation in HUVEC (16).
Nevertheless, the implication of HO-1 in the protection of
glomerular endothelium has not, to our knowledge, been studied.
We here show that endothelial heterogeneity is apparent
under hemolytic conditions: the microvascular EC, and
particularly the glomerular EC, become vulnerable to injury
through differences in their C3 regulation and heme degradation
compared with macrovascular EC. These results might explain,
at least in part, the renal tropism of complement-mediated TMA
lesions in aHUS.
MATERIALS AND METHODS
Reagents
The oxidized form of heme (hemin, ferriprotoporphyrin
IX), designated as heme, (Sigma or Frontier Scientific) and
Sn(IV) mesoporphyrin IX (SnMPIX) (Frontier Scientific) were
suspended at 10mM in 50mM NaOH, 145mM NaCl, and
therafter diluted in the appropriate vehicle (medium for culture
cells, PBS for animal experimentation).
Animal Experimentation
All experiments were conducted in accordance with the
recommendations for care and use of laboratory animals of the
French Ministry of Agriculture and with the approval of the
Charles Darwin Ethics Committee for animal experimentation
(Paris, France) number APAFIS#3764-201601121739330v3.
Six to eight-week-old female C57Bl/6 mice from Charles
River Laboratories (L’Arbresle, France) were treated with
intraperitoneal injection of 200 µL phosphate buffer saline (PBS,
Dulbeco) or freshly prepared heme (40µmol/kg corresponding
to 27µg/g body weight) at day 0 and 1. At day 2 mice were culled
and the organs were then recovered: kidneys, lungs, heart and
skin (1 cm²) were preserved directly in plastic molds containing
optimal cutting temperature (OCT) compound, placed on dry
ice and frozen. Brains were otherwise frozen in isopentane at
−70◦C to preserve the tissue architecture before being placed in
OCT and frozen.
Immunohistochemistry (IHC) and
Immunofluorescence (IF)
Frozen organs sections (6µm)were fixed in acetone. The primary
antibodies were: Heme Oxygenase-1 (HO-1; rabbit anti-mouse,
Abcam Ab13243, 5µg/ml), C3b/iC3b (rat anti-mouse, Hycult
biotech, HM1065, 1µg/ml), Thrombomodulin (TM; rabbit
anti-mouse, R&D systems, MAB3894, 20µg/ml), CD31 (rat
anti-mouse, Abcam Ab7388, 2µg/mL), von Willebrand Factor
(vWF; sheep anti-mouse, Abcam, Ab11713, 1/100). Staining was
revealed by goat anti-rabbit AF647 (Thermoscientific, A21244,
5µg/mL) or goat anti-rat AF555 (Thermoscientific, A21434,
5µg/mL). Slides were scanned by Nanozoomer (Hamamatsu)
and AxioScan (Zeiss) for IHC and IF, respectively.
Endothelial Cells Assays
Cells Culture
Human umbilical vein endothelial cells (HUVEC—a model
of macrovascular EC), a human dermal EC line (HMEC—a
microvascular EC model), conditionally immortalized (GENC)
and human primary (HRGEC) glomerular EC were compared.
HUVEC (n= 7 donors) were obtained from CHU Lille (France),
HMECwere fromATCC (17) (US), GENCwere fromDr. Satchell
(Bristol, UK) (18) and HRGEC (n = 3) were from iCelltis
(Toulouse, France). Cells were cultured as previously described
(9, 10, 18): briefly, the growth medium was M199 20% fetal calf
serum and 20% EGM2-MV (Lonza) for HUVEC, and EGM2-
MV for the other cell types. HUVEC and HRGEC were used for
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experiments until passage 4, HMEC between passages 2–7 and
GENC between passages 23 and 30. Cells were exposed to heme
at indicated doses overnight or for 30min in serum-free medium
OPTI (Thermo Fisher), or overnight to the pro-inflammatory
cytokines TNFα and IFNγ (PeproTech) at 10 ng/ml and 103
U/ml in complete medium, respectively. Alternatively, HUVEC
were exposed to heme or SnMPIX overnight before being re-
challenged, or not, with 50µMof heme. Dead cells were removed
by washing. Normal human serum (NHS) was used as a source of
complement.
Flow Cytometry
Cells were washed, detached, labeled and analyzed by flow
cytometry (BD LSR II), and the data assessed using FCS
Express software (De Novo software). Antibodies were diluted
in PBA (PBS, BSA 0.5%, Azide 0.1%): anti-C3c (Quidel, A205,
10µg/ml), anti-FH (antiFH#1, Quidel, A229, 55µg/ml), anti-
MCP-PE (Bio Rad, MCA2113, 10µg/ml), anti-DAF (Bio Rad,
MCA1614, 10µg/ml). Staining was revealed by goat anti-mouse
IgG PE (Beckman Coulter, IM0551). Cell viability was followed
by annexin V-APC/DAPI staining (BD Bioscience).
RTqPCR
RNA extraction from cells was performed with a Qiagen
kit. Quality and quantity of RNA were measured by an
Agilent 2100 Bioanalyzer (Agilent Techonologies). RNA
Integrity Number was considered acceptable if >9. After
standard RT-PCR, amplification of cDNA was proceeded with
following probes: actin-4332645, TM-hs00264920-s1, HO-1-
hs01110250_m1, KLF2-Hs00360439_g1, KLF4-Hs00358836_m1,
NRF2-Hs00975961_g1, BACH1-Hs00230917_m1. Data were
analyzed by SDS2.3 and RQ manager software. The mean cycle
threshold (CT) values for both the target and internal control
(β-actin) were determined for each sample. The fold change
in the target gene, normalized to β-actin and relative to the
expression of untreated HUVEC, was calculated as 2–11CT
(19).
Western Blot (WB)
Cells were lysed in RadioImmunoPrecipitation Assay (RIPA)
buffer and deposited at 10µg/ml on 10% pre-casted gels
(Life Technology). After transfer, the HO-1 and actin were
probed by a rat anti-human HO-1 IgG2b (R&D systems,
MAB3776, 2µg/ml) and a rabbit anti-actin (Sigma Aldrich,
A2066, 1/10000). Secondary antibodies were goat anti-rat IgG-
HRP (R&D systems, HAF005, 1/5000) and goat anti-rabbit IgG-
HRP (Santa Cruz Technology, sc-2004, 1/10000). Blots were
revealed by chemiluminescence (Super Signal West, Extended
Duration Substrate, Thermoscientific myECL).
Study of C3b Cleavage
To study the contribution of TM to the cleavage of C3b by
Factor I (FI) in the presence of Factor H (FH) as a cofactor,
purified C3b (Calbiochem), diluted in Tris buffer (10mM, NaCl
40mM, pH7.4) at 20µg/ml (300 µl), was incubated with human
albumin (CSL Behring, 10µg/ml), TM (R&D Systems, 10µg/ml,
10 µl), or without protein for 10min on ice. FH (20µg/ml, 10
µl) was added on ice for 10min. Each sample was separated into
4 tubes, and 4 µl of FI (10µg/ml) was added per tube. DTT-Blue
Reducing sample buffer (13µL) was added at t= 0, 30 s, 2min or
10min to stop cleavage of C3b. Samples were denatured, resolved
on a 10% gel and transferred onto a nitrocellulose membrane.
The antibodies used for visualization by WB were an anti-C3
polyclonal goat antiserum (Merck Millipore, 204869, 1/5000)
and a goat anti-rabbit antibody IgG-HRP (Santa Cruz, sc-2004,
1/5000).
Patients’ Kidney Biopsies
Biopsies from two aHUS patients - P1 carrying C3 p.R161W [C3
gain of function (9)] and P2, having homozygous FH mutation
p.C564F (FH deficiency)—were retrieved from the archive of the
Pathology Institute of CHU Lille, France. P1 had a hemolytic
anemia and histological analysis described typical lesions of
glomerular and arteriolar TMA. Hemolysis was corrected at the
moment of P2 biopsy, which reported predominant chronic
TMA lesions, characterized by vessel wall thickening and
thrombotic occlusion of many arterioles. Perls’ Prussian blue
staining identified hemosiderin deposits. Immunohistochemical
analysis for HO-1 (rabbit anti-HO-1, Abcam) was performed
on deparaffinized slides using Ventana XT autostainer (Ventana
Medical systems). Immunofluorescence with rabbit anti-C3c
(Dako) was performed on frozen slides. Secondary antibodies
were coupled to Fluorescein IsoThioCyanate—FITC (Sigma
Aldrich). A normal protocol, kidney allograft biopsy performed
3 months after transplant was used as a negative control and
biopsies of two patients with chronic hemolysis (hemolysis
associated with prosthetic heart valve) were used as positive
controls for hemosiderin detection and tubular staining of
HO-1 (20). Whole slides were scanned or analyzed by an
Olympus microscope (Life Sciences Solutions) or Nanozoomer
(Hamamatsu).
Statistics
Statistical analysis was performed with R software (21). The
ggplot2 package (22) was used for graphical representations.
Data are presented as medians and interquartile ranges. After a
Kruskal-Wallis test, a Dunn’s test was used for multiple pairwise
comparisons. A p-value<0.05 was considered significant.
RESULTS
Heme-Induced C3 Fragment Deposition
With a Particular Renal Tropism in vivo
We performed a comparative analysis of the deposition of C3
activation fragments in mouse organs under control conditions
(injection of PBS) and after administration of heme using IF
(Figure 1) and IHC (Supplementary Figure 1). No structural
differences were detected in the kidneys or livers of heme-
injected mice (Periodic Acid Schiff (PAS) and hematoxylin,
eosin, saffron (HES) staining), in agreement with previous
observations (13).
IHC staining for C3 activation fragments revealed
minimal/absent staining in the three tested organs: kidney,
heart and liver of PBS-injected mice. In heme-injected mice,
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FIGURE 1 | Heme-induced complement C3 fragment deposition with a particular renal tropism in vivo. (A-F) C3b/iC3b staining (red), wWF staining (green) and
colocalization vWF—C3b of frozen kidney x15 (A), heart x15 (B), liver x8 (C) brain x8 (D), skin x15 (E), and lung x5 (F); sections of mice treated with PBS (negative
control, upper panel) or heme (lower panel) studied by immunofluorescence. Representative images of 3 independent experiments with 3 or 5 mice per group.
significant deposits were observed in kidney glomeruli,
while only minimal effects were observed in heart or liver
using this technique (Supplementary Figures 1A–C). We
also studied the C3 fragment deposition using the more
sensitive IF method. C3 staining was detected in kidneys
of PBS-injected mice, located along the tubular basement
membrane and in the Bowman’s capsule (Figure 1A); it
was minimal/absent in heart, liver, brain, skin and lungs
of these mice (Figures 1B–F). In the presence of heme,
strong C3b/iC3b staining was detected in kidneys (Figure 1A,
Supplementary Figure 1D) contrary to heart and brain
(Figures 1B,D). To a lesser extent, deposits were also revealed
in liver, skin and lungs (Figures 1C,E,F). In the heme-exposed
kidneys themselves, C3 fragment deposits were observed in
vessels, intra-glomeruli, along the tubular basement membrane
and in the Bowman’s capsule. C3 deposits were detected on the
glomerular EC, as seen by double staining for C3b/iC3b and
vWF (Supplementary Figure 1D).
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Long-Term Exposure to Heme Rendered
Glomerular Endothelial Cells Susceptible
to Complement Activation in vitro
We then tested whether the particular susceptibility of the
glomerular endothelium to C3 activation fragment deposition
could be reproduced in vitro, using cultured human EC from
different vascular beds (Figure 2A). We compared human
primary (HRGEC) and conditionally immortalized (GENC)
glomerular cells with HUVEC (as a macrovascular EC model)
and human microvascular EC line (HMEC), for their capacity
to activate complement after exposure to heme. In accordance
with the in vivo data, C3 deposits were significantly higher
on glomerular EC (GENC and HRGEC) than on HUVEC and
HMEC (p< 0.05). Overnight exposure to 50µM heme increased
C3 deposition on average ∼2.6 fold on HUVEC, ∼4 fold on
HMEC, ∼7.5 fold on GENC and ∼6 fold on HRGEC compared
with the baseline. No significant difference was observed in terms
of C3 fragment deposition at resting state on the tested EC
(Figures 2B,C).
Others TMA-related stimuli were tested, such as exposure to
pro-inflammatory cytokines TNFα and IFNγ (deemed pertinent
as the primary trigger for aHUS could be an infection) or brief
exposure (30min) to heme [since hemolysis has been proposed as
a secondary hit for aHUS (8)]. In both cases HUVEC and GENC
showed a similar response profile, with increased C3 fragment
deposition from NHS, but without significant difference between
the cell types in either the resting state or in the 30min heme-
exposed cells, while GENC had lower levels of C3 deposition
compared to HUVEC after activation by the pro-inflammatory
cytokines (p< 0.0001) (Figure 2D).
The Increase of C3 Deposition on
Glomerular EC Correlates With a Weaker
FH Binding
Most cells adapt over the long term to resist to heme overload.
Therefore, we compared the binding/expression of complement
regulators after overnight exposure to heme (Figure 3). We
detected a heme-concentration-dependent increase of FH
binding from NHS, significantly higher on HUVEC, compared
with the glomerular EC (p < 0.05) (Figures 3A,B). The
expression of MCP and DAF did not differ among the four tested
EC types at resting state (Supplementary Figures 2A,B), while
under hemolytic conditions MCP decreased to a similar level for
the four cell types and DAF displayed a heterogeneous behavior
(Figures 3C,D).
TM Is Inefficiently Upregulated on
Heme-Exposed Microvascular EC in vivo
and in vitro
The susceptibility of microvasculature to TMA could be
related not only to lower resistance to complement but
also to inefficient thromboresistance or regulation of the
coagulation cascade. TM is a key factor in reducing blood
coagulation, but may serve also as complement regulator
(23). Here, TM accelerated the cleavage of C3b to iC3b by
FI, leading to the appearance of the α43 fragment at 30 s
with a time-dependent increase; this band was invisible in
the presence of albumin (irrelevant protein) or buffer at
30 s, appearing later (2min) with a time-dependent increase
(Figure 4A).
In vitro, the expression of TM did not differ among the four
tested EC types at resting state (Supplementary Figure 3). After
prolonged exposure to heme, TM gene expression (Figure 4B)
increased in HUVEC (gene expression ∼6.1 fold at 50µM
heme, compared to baseline), while it was significantly lower
in HMEC, GENC, and HRGEC (p < 0.05) compared with
HUVEC. The TM level was also evaluated in different organs
of heme-injected mice (Figure 4C). No difference was detected
in glomeruli (strong basal staining) nor in heart or brain
of heme- vs. PBS-injected mice. In contrast, a tendency
toward an increase of TM was detected in skin, and a
significant 18-fold increase of TM staining was found in the
large vessels of the livers from heme-injected mice compared
with PBS controls (p < 0.05). Surprisingly, an over 30-fold
decrease of TM was seen in the lungs’ microvasculature of
heme-injected mice compared with controls (p < 0.0001)
(Figure 4C).
Heme Oxygenase-1 (HO-1) Is Inefficiently
Upregulated on Microvascular and
Particularly on Glomerular Endothelium by
Heme in vitro and in vivo
The susceptibility of the kidney to TMA lesions could be also
related to a reduced resistance to oxidative stress and inefficient
heme-degradation. HO-1 is the major heme-degrading enzyme
and its expression is inducible after cell stress (15).
In mice, at basal condition (PBS), HO-1 staining was negative
in the kidney (Figure 5A) as well as in others studied organs
(Figures 5B–F). After heme injection, HO-1 staining was intense
in the proximal tubules, but remained negative in glomeruli
(Figure 5A, Supplementary Figures 4A,B). The same results
were observed by IHC. Onlyminimal HO-1 staining was detected
in some cases in heme-exposed glomeruli, corresponding to
the glomerular epithelial cells and not endothelial cells in
agreement with previous reports for human glomeruli (24); HO-
1 expression was not detected in the brains of the heme-treated
mice either. HO-1 labeling was positive in heart, liver, skin
and lungs of heme-treated animals (Figures 5B–F), and visual
colocalization with blood vessels was observed. In the skin, the
HO-1 expression was particularly strong in the vessels of the hair
follicles.
In vitro, heme-treatment induced ∼92.3 fold increased
HO-1 gene expression on HUVEC, compared to baseline
(Figure 6C).This increase was weaker in the other cell types:∼5.9
fold on HMEC (p < 0.05), ∼26.6 fold on GENC (p < 0.05)
and ∼17 fold on HRGEC (p < 0.05). HO-1 protein expression
level in HUVEC, and to a lesser extent HMEC, increased with
increasing heme concentration (Figures 6A,B—note that HMEC
are derived from cells isolated from human foreskins and lack
hair follicles). Meanwhile, HO-1 expression on both glomerular
EC types was only weakly detected.
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FIGURE 2 | Influence of heme and cytokines on C3 fragment deposits on cultured human EC. (A) Experimental settings of figures (B–D) study by flow cytometry of
C3b/iC3b deposition on cultured human EC (HUVEC, HMEC, GENC, HREGC), pretreated with medium only, TNFα/IFNγ overnight, or 50µM of heme (30min or
overnight) before incubation with 33% NHS diluted in M199 culture medium and non-enzymatic detachment. (B) C3b/iC3b fragment deposits on resting EC (gray
histograms) or EC treated overnight with 50µM of heme (red histograms). Isotype control IgG1 appears as a black histogram (Iso). Representative histograms of 3
independent experiments. (C) Quantification of C3b/iC3b fragments deposition on the four EC types, studied as a function of the dose of heme overnight (n = 3–5).
(D) Quantification of C3b/iC3b fragments deposition on HUVEC and GENC pretreated with medium only, TNFα/IFNγ overnight, or 50µM of heme (30min) (n = 3–5).
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FIGURE 3 | Influence of heme on C3 convertase regulators on cultured human EC. Experimental settings are similar with Figure 2. (A) Binding of FH on resting EC
(gray histograms) or EC treated overnight with 50µM of heme (red histograms) before incubation with sera. FH binding was analyzed by flow cytometry. Isotype
control IgG1 appears as a black histogram (Iso). Representative histograms of 3 independent experiments. Quantification of the (B) FH, (C) MCP, and (D) DAF
staining, studied as a function of the dose of heme (n = 3–5).
HO-1 Is Inefficiently Upregulated in
Patients’ Glomerular Endothelium
In kidney biopsies of patients with hemolysis—aHUS or
with prosthetic cardiac valve—IHC with anti-HO-1 revealed
a tubular staining proportional to the degree of hemolysis
observed by hemosiderin deposition by Perls’ Prussian blue
staining (Figure 6D). Glomerular endothelium HO-1 staining
was negative (Figure 6E). No hemosiderin deposition, HO-
1 mesangial or tubular stainings were detected in negative
controls. It should be noted that all biopsies, even negative
controls, displayed non-specific staining due to capture
of the antibody by erythrocytes. Positive staining was
nevertheless detected on podocytes, in agreement with
previous observations (25). Similar to the mouse results,
weak positive C3 staining was detected in some glomeruli
of cardiac valve patients, while intense deposits were
observed in the patients with complement abnormalities
(Figure 6F).
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FIGURE 4 | Influence of heme on the TM expression in vitro on cultured human EC and in mice. (A) Functional activity of TM as complement regulator, studied using
purified protein by western blot. C3b is composed of 2 chains, α and β, visible by WB as 2 bands. The α chain is cleaved by FI to give two new bands: α67 and α43.
The intensity of these bands reflects the level of C3b conversion to iC3b. Incubation of C3b with FH and FI led to cleavage of C3b to iC3b in a time-dependent
manner. Addition of TM accelerates the cleavage of C3b compared to albumin and buffer controls. (B,C) HUVEC, HMEC, GENC, and HRGEC were incubated with
increasing concentrations of heme overnight and mRNA was extracted. Gene expression of (B) TM was measured by RTqPCR, (n = 3). (C) TM staining (in red) was
studied by IF in frozen kidney (x15), heart (x15), liver (x8), brain (x8), skin (x15), and lung (x5) sections of mice treated with PBS (negative control) or heme.
Representative images of 5 mice per group. Lower panels: quantification of TM staining in organs sections of PBS (white) and heme-injected mice (gray).
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FIGURE 5 | Comparison of HO-1 expression in different organs after heme injection in mice. (A-F) vWF (green) staining, HO-1 (red) staining and colocalization on
frozen kidney (x15), heart (x15) liver (x8), brain (x8), skin (x15), and lung (x15) sections of mice, injected with PBS (upper panel) or heme (lower panel), studied by IF.
Representative results of 3 independent experiments with 3 or 5 mice per group.
Glomerular EC Fail to Accommodate a
Second Challenge With Heme and Show
Enhanced C3 Deposition
The HO-1 up-regulation is accompanied by accommodation
and a gain in complement resistance in HUVEC (16). We
here compared the C3 deposition on the four EC types after
incubation overnight with different doses of heme (to induce
HO-1 upregulation), followed by a second challenge with 50µM
of heme for 30min and exposure to serum (Figure 7A). The
30min heme-exposure caused about a 2-fold increase of the C3
deposition on EC not receiving heme overnight (not shown).
Exposure to heme overnight followed by 50µM heme for
30min produced a dose-dependent decrease in C3 deposition
on HUVEC, but an increase on glomerular EC (Figure 7B).
C3 deposits decreased by ∼50% on HUVEC, while they
significantly increased by ∼8 fold on GENC and ∼3 fold on
HRGEC (p < 0.05) compared with HUVEC. HMEC showed
an intermediate phenotype with C3 deposition comparable to
baseline.
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FIGURE 6 | Influence of heme on the HO-1 expression in vitro in cultured human EC and HO-1 expression and C3b deposition in human kidney biopsies under
hemolysis (A–C) HUVEC, HMEC, GENC, and HRGEC were stimulated with increasing concentrations of heme overnight. (A) HO-1 protein level studied by western
blot (n = 2–5). (B) Quantification of the western blots (n = 2–5), ratio of the band of HO-1, relative to the band of actin. (C) HO-1 gene expression measured by
RTqPCR (n = 3). (D) Hemolysis level on human kidney biopsies was evaluated by the hemosiderin deposits, revealed by Perls’ coloration. (E) HO-1 (brown) and (F)
C3 (green) staining were performed by IHC and IF, respectively. A normal protocol, kidney allograft biopsy performed 3 months after transplant was used as a negative
control. Biopsies of a patient with chronic hemolysis (hemolysis associated with prosthetic heart valve) were used as a positive control. Two patients with aHUS
carrying complement mutations were tested.
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To find out to what extent this protective effect in HUVEC
was HO-1 dependent, the HO-1 expression was induced by
pre-incubation with another porphyrin of similar structure to
heme (SnMPIX) but which blocks its activity (26–28). Overnight
exposure of the cells to SnMPIX caused HO-1 expression, albeit
2–3 fold weaker than that induced by exposure to heme, and
no increase of C3 deposition (data not shown). After a second
challenge with heme, no protective effect against complement
of the pre-incubation with SnMPIX was detected at any of the
tested doses (up to 50µM), contrary to heme which produced a
protective effect after cells were exposed at 12.5µM heme (p <
0.05) (Figure 7C).
TM and HO-1 Expression May Be Parallel
Phenomena, Dependent on the
Transcription Activity of KLF2 and KLF4
HO-1 expression is mainly dependent of the transcription factors
NRF2 and BACH1, but no major differences were found for their
expression between the four EC types (Figures 7D,E), except
for a slightly lower expression of NRF2 at resting state for the
glomerular HRGEC (p< 0.05).
We then studied transcription factorsKLF2 and KLF4 because
they control the expression of TM (29), and KLF4 could also
modulate HO-1 expression (30). For KLF2, a strong dose-
dependent effect was noted in HUVEC with ∼9.8-fold increase
compared with untreated cells after exposure to 50µM of heme
(Figure 7F). The increase in the other cell types was lower
compared to HUVEC, with only ∼2, ∼3.3, and ∼3.8-fold after
exposure to 50µM heme for HMEC, GENC, and HRGEC,
respectively. StrongKLF4 gene expression was also observed with
increases in heme concentration (Figure 7G). Exposure to 50µM
heme induced ∼25-fold increase of KLF4 level in HUVEC,
but only ∼1.26, ∼1.1, and ∼1.48-fold in the microvascular
HMEC, GENC, and HRGEC, respectively. These results may be
explained, at least in part, by the shared profile of TM and HO-1
expressions in microvascular EC.
DISCUSSION
In this study, we discovered a dichotomy in the phenotypic
adaptation to hemolysis of macro- vs. microvascular
endothelium. Macrovascular EC adapted to heme-overload
by up-regulating the heme-degrading HO-1 and the coagulation
and complement regulator TM, as well as exhibiting enhanced
binding of the complement regulator FH. On the contrary,
the microvascular EC, and in particular glomerular EC, were
less efficient at each of these processes (Figure 8A), which
resulted in a susceptibility of glomerular endothelium to heme-
driven complement overactivation. These observations may
help to explain the microvascular and renal tropism of the
complement-mediated TMA lesions of aHUS (Figure 8B).
The tropism of TMA lesions for small vessels is a defining
feature of this group of syndromes, but the mechanisms remain
poorly described. Our results and data from the literature suggest
that resting microvascular EC express similar or even higher
levels of complement regulators and TM (6, 31, 32), failing thus to
explain their susceptibility to TMA lesions. It is well-established
that the presence of shiga toxin in typical HUS, complement
abnormalities in aHUS, or ADAMTS13 deficiency in thrombotic
thrombocytopenic purpura (TTP) are necessary but not sufficient
in themselves to trigger TMA (1, 33). Inflammatory insult is
a frequently described TMA-trigger. Nevertheless, our results
showed that inflammatory mediators increased complement
activation and decreased TM expression in both micro- and
macrovasular EC, in accordance with previous studies (6, 33–
35). Secondary hits are needed to overcome the tolerable EC
stress and to promote overt endothelial injury and disease
manifestation. Since hemolysis is a hallmark of TMA, it is
tempting to speculate that oxidative stress and cell activation will
be particularly noxious for the microvessels, in the kidney as well
as other organs, amplifying cell damage, complement activation
and thrombosis, contrary to macrovessels.
Hemolysis alone also does not induce renal TMA lesions
(13) but may present a secondary challenge in the presence
of deregulated complement, as in the case of aHUS (7, 8);
indeed, heme activates complement AP directly in serum
and this contributes to the C3 deposits found on EC (8,
11, 36–39). In support of this hypothesis, injection of heme
resulted in a marked renal C3 deposition in mice, localized
predominantly in the glomeruli, and similar to what has been
observed for intravascular hemolysis and injection of cell-free
hemoglobin (39). In contrast to kidneys, our examination of the
heart, liver, brain, skin and lungs showed them to be largely
unaffected by injection of heme, or to have exhibited only
small increases in C3 deposits after injection (summary in the
Supplementary Table 1). In agreement with these in vivo data,
overnight exposure to heme induced stronger C3 deposition
on glomerular EC compared with the macrovascular (HUVEC)
and microvascular (HMEC) cell models. Together, these in
vivo and in vitro observations point toward a vulnerability
of the glomerular endothelium to complement deposition in
the presence of heme. However, the inefficient adaptation to
hemolysis in terms of HO-1 expression and TM up-regulation
was also observed in other microvascular EC, both in vitro and in
vivo, while only glomerular EC were subject to deposition of very
high levels of C3 activation fragments upon exposure to heme.
These particularly elevated complement deposits in kidneys
and glomerular cells may be explained by reduced binding
of FH, the main regulator of the AP of complement (3),
which is the most frequently affected among aHUS patients
[genetic or acquired abnormalities found in >40% of patients
(2, 40, 41)]. Moreover, we confirmed that FH is assisted
by TM in the inactivation of C3b (23, 42, 43) and that
the lower level of TM can further aggravate the inefficient
complement regulation. The underlying mechanism(s) behind
this reduced FH binding require further investigation, but the
combination of decreased FH binding to glomerular EC under
hemolytic conditions with FH mutations or autoantibodies
could contribute to the susceptibility of glomerular EC to TMA
lesions. Interestingly, a recent study also showed that renin, an
enzyme produced specifically in the kidney, could cleave C3
and exacerbate the complement activation (44). The hemolysis-
mediated complement activation could be an additional key
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FIGURE 7 | Influence of porphyrin pre-incubation on C3 fragments deposition on EC and expression of HO-1 and TM transcription factors (A) Experimental settings
of B and C: C3 fragments deposition study, on cultured human EC pretreated overnight with medium only or pre-incubated with porphyrin (heme or SnMPIX) and then
rechallenged by 50µM of heme during 30min, followed by incubation with 33% NHS. C3b/iC3b staining was analyzed by flow cytometry. (B,C) C3 fragments
deposition under the experimental conditions described above as a function of the dose of heme during the pre-incubation step (B) on EC, and as a function of the
dose of heme or SnMPIX (C) during the pre-incubation step on HUVEC (n = 3). (D–G) HUVEC, HMEC, GENC, and HRGEC were stimulated with increasing
concentrations of heme overnight. (D) NRF2, (E) BACH1, (F) KLF2, and (G) KLF4 gene expression measured by RTqPCR (n = 3).
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FIGURE 8 | Schematic representation of our model to explain the glomerular vulnerability to complement-mediated TMA. (A) Heat map, illustrating the variations of
the studied parameters between the four EC types. Results of the fold difference of gene or protein expression or binding with exposure to 50µM heme were analyzed
using Genesis software. White color indicates no difference (fold change 1), blue indicates reduction and red an increased expression/binding. (B) Proposed model to
(Continued)
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FIGURE 8 | explain the microvascular/glomerular cell susceptibility of TMA lesions. Our results suggest that hemolysis is a key factor in the vulnerability of the
glomerular EC complement overactivation and TMA. The glomerular EC have a weaker capacity to adapt to hemolysis and to up-regulate cytoprotective and
stress-response genes, such as HO-1 and TM, compared to EC from other organs. This could be related to the lower levels of the transcription factors KLF2 and
KLF4. The inefficient degradation of heme due to the lack of HO-1 will result in stronger heme-mediated complement activation on the endothelium. The weaker
expression of TM will on the one hand contribute to the pro-coagulant phenotype of the EC, and on the other hand contribute to inefficient degradation of the
anaphylatoxins C3a and C5a and assist FH and FI in degradation of C3b. Finally, FH will bind less to heme-exposed glomerular EC compared to EC of other organs.
This will be further exacerbated in case of complement overactivation, as in aHUS, leading to EC suffering and TMA.
element in this vicious circle, linking renin secretion, vascular
damage and renal failure. Thus, the C3 deposits described in
aHUS kidney biopsies, which are generally considered non-
specific (45, 46), could reflect the complement activation due
to hemolysis and deregulated complement, this last condition
explaining why the C3 deposits are greater in aHUS patients than
in cases of isolated hemolysis (cardiac valve).
The cells’ capacity to express HO-1, to degrade heme and then
detoxify it to cytoprotective metabolites biliverdin and CO, plays
a key role in vascular protection (15, 47). In vitro studies have
shown heme-mediated HO-1 expression in HUVEC (48, 49),
and there is clear evidence for endothelial HO-1 expression in
large vessels of patients with sickle cell disease (50), as well as
in animal models of hemolysis or other stress inducers (51–55).
In contrast, we found only HO-1 upregulation to be minimal
or absent in glomerular EC (in vitro or in vivo), in aHUS
and hemolytic patients, as well as in heme-injected mice. This
observation is in agreement with published images of aHUS
and under other hemolytic conditions (20, 24, 25, 56, 57)
and indicates that glomerular endothelium does not have the
capacity to efficiently up-regulate HO-1 in presence of heme.
HO-1 production is, however, indispensable to the glomerular
protection, as suggested by reported early damages of glomeruli
in case of HO-1deficiency in murine model or in human (47, 58,
59). Mesangial proliferation and thickening of the capillary wall
in accordance with endothelial swelling and detachment were
indeed described in a HO-1 deficient young boy. This early aspect
of mesangioproliferative glomerulonephritis was confirmed from
sequential kidney samples (at 2, 5 and 6 year-old), while tubulo-
interstitial damages advanced more progressively. This could
to be related to the fact that the production of HO-1 within
kidneys would be mainly tubular, while in the glomeruli the
major HO-1 source would be the infiltrating macrophages, not
the intrinsic glomerular cells (60). Further studies are needed
to extend our knowledge on the different ways, that the EC
from different vascular beds manage heme homeostasis, based
on their specific ability to accumulate it, to transport it within
the cell by FLVCR1, to express ferritin, store iron and to
produce reactive oxygen species. Some of these parameters have
been studied for HUVEC and HMEC, especially in the context
of deficiency of the heme transporter FLVCR1a, but data on
glomerular EC are lacking (61). Moreover, a recent study in
the context of leukemia demonstrated that C3a and C5a trigger
phosphorylation of MAPK, followed by downregulation of HO-1
expression in malignant cells (62). If such phenomenon operates
in HO-1 expressing endothelium, complement activation by
intravascular hemolysis and heme release may weaken the
endothelial resistance. In such context, inhibitors of MAPK
(such as SB203580) will result in upregulation of HO-1 and
enhance resistance to hemolysis-derived products as well as to
complement.
A protective role of HO-1 against immune complexes-
mediated complement overactivation has also been described on
HUVEC (16). Here, our results demonstrated a complement-
protective effect of pre-incubation with heme in HUVEC. Ideally,
this phenomenon should be confirmed after HO-1 silencing. In
contrast, the glomerular EC showed a marked increase in C3
deposition. These results, together with the loss of this protective
effect upon HO-1 inhibition in HUVEC, suggest that HO-1
activity for heme degradation contributes to protection against
complement activation in this cell type—a phenomenon which is
not operational in the glomerular endothelium. It is important
to note that glomerular EC were able to upregulate HO-1
after incubation with a very potent inducer, such as CoPPIX
(data not shown), suggesting that the machinery needed for its
synthesis is present and can be triggered after potent stimulation.
Nevertheless, induction of massive hemolysis in vivo was not
strong enough to mediate HO-1 staining in glomerular EC,
contrary to tubuli and podocytes [(13) and data not shown].
Our in vivo experiments also showed that the brain endothelium
failed to upregulate HO-1 after heme injection, but this was
not associated with concomitant deposition of C3 fragments.
Sartain et al. recently demonstrated that brain microvascular
EC express higher levels of complement regulators, compared
to glomerular EC, and had a better capacity for suppressing
the alternative pathway in vitro (32). These findings may help
to explain the occurrence of lower levels of cerebral vessels’
complement deposits and the fact that in aHUS, as well as in
shiga toxin HUS, brain manifestations were found in only a
small fraction of patients (63). On the other hand, the inefficient
upregulation of HO-1 in the brain vasculature may contribute
to the cerebral manifestations of TTP (also a TMA disease).
The possible role of HO-1 expression in TTP pathophysiology
requires further studies.
Interestingly, KLF2 (64, 65), and KLF4 (66), which are known
transcription factors of TM, have also been shown to serve as
modulators of HO-1 expression (30). Therefore, the weaker up-
regulation of TM and HO-1 we observed in microvascular EC
could at least in part be related to differences in transcription
regulation. Consistent with these data, other workers have
reported that KLF2 and KLF4 were not significantly upregulated
in glomeruli of aHUS patients compared with controls (67).
The observed differences in gene expression and phenotype
among the tested EC here confirm the utility of HUVEC
and HMEC as model EC types for macro- and microvascular
endothelial, but highlight unique features and responses to
activation in glomerular EC, which could perhaps be better
modeled by glomerular (primary or cell line) EC in culture. A
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limitation of our work is that, although we observed correlations,
we do not provide direct evidence linking HO-1 and complement
deposits in vitro, for which the knock out/knock in strategy
would have been useful. Also, providing in vivo evidence that
up-regulation of HO-1 could prevent complement activation and
TMA lesions in a mouse model of aHUS was outside the scope of
this study.
In conclusion, we have shown that when compared with
macrovascular EC, microvascular EC, and glomerular EC in
particular, are vulnerable to complement-mediated TMA at
least in part because of their failure to adapt to hemolysis,
to up-regulate cytoprotective and stress-response genes such as
HO-1 and TM, and to bind FH (Figure 8B). We hypothesize
that local, subclinical microthrombosis due to a primary
triggering event (infection, pregnancy) will cause mechanical
hemolysis in the kidney. By amplifying complement activation
and pro-thrombogenic traits, heme will exacerbate endothelial
activation. Once the threshold of tolerance is reached, this
heme-induced endothelial and complement overactivation could
sustain and perpetuate the TMA lesions. Together, our
results indicate that the vulnerability of the glomerular
EC to hemolysis is a key factor, predisposing them to
complement overactivation and TMA, as seen in aHUS. The
heme scavenger protein hemopexin has been efficient in
preventing hemolysis-mediated C3 deposition in kidneys in a
mouse model of intravascular hemolysis and on endothelial
cells in vitro (39), as well as in models of stasis in
sickle cell disease (68) or other hemolytic conditions (69).
Therefore, heme-blocking agents may be explored as novel
therapeutic strategies to prevent microvascular injury in TMA
diseases.
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